Can upadacitinib be used off‑label to treat moderate‑to‑severe vitiligo in adults who have failed topical corticosteroids, calcineurin inhibitors, or narrow‑band UVB phototherapy?

Upadacitinib for Moderate-to-Severe Vitiligo

Yes, upadacitinib 15 mg once daily can be used off-label for adults and adolescents (≥12 years) with moderate-to-severe non-segmental vitiligo who have failed topical corticosteroids, calcineurin inhibitors, or narrow-band UVB phototherapy, based on recent phase 3 trial data showing clinically meaningful repigmentation with an acceptable safety profile.

Evidence Supporting Use

The most compelling evidence comes from two phase 3 randomized controlled trials (Viti-Up-1 and Viti-Up-2) completed in 2024, which demonstrated that upadacitinib 15 mg daily achieved:

• T-VASI 50 (≥50% total body repigmentation) in 19-21% of patients versus 6% with placebo at 48 weeks (p<0.001) 1
• F-VASI 75 (≥75% facial repigmentation) in 23-25% of patients versus 6-7% with placebo at 48 weeks (p<0.001) 1

These results represent clinically meaningful repigmentation, particularly important given that facial involvement carries the highest psychosocial burden.

Dosing and Patient Selection

Recommended approach:

• Start with upadacitinib 15 mg once daily orally 1, 2
• Target patients with non-segmental vitiligo, F-VASI ≥0.5, and T-VASI 5-50 1
• Continuous treatment shows progressive repigmentation through 52 weeks without plateau 2

Higher doses (22 mg) showed increased adverse events without proportional efficacy gains and should be avoided 2

Efficacy Timeline

Expect gradual improvement:

• Phase 2 data showed mean F-VASI improvement of -21.27% at 24 weeks with 11 mg dose 2
• Continuous repigmentation observed through 52 weeks without reaching plateau 2
• Real-world case series confirmed repigmentation within 4 months 3

Safety Considerations and Monitoring

Pre-treatment screening required:

• Screen for latent tuberculosis
• Check baseline CBC, liver enzymes, lipid panel, creatinine
• Assess VTE risk factors: age >65, prior VTE, thrombophilias, obesity, recent surgery, immobility, smoking 4
• Evaluate renal function (adjust dose if eGFR <30 mL/min) 5
• Assess hepatic function (contraindicated in Child-Pugh C) 5

Monitoring during treatment:

• CBC, liver enzymes at 4-8 weeks, then periodically 5
• Lipid panel at 8 weeks 5
• Monitor for infections, particularly herpes zoster

Safety profile from phase 3 trials:

• No major adverse cardiovascular events, VTE, GI perforations, or opportunistic infections (except herpes zoster) 1
• Most common adverse events: COVID-19, headache, acne, fatigue 2
• One serious nonfatal ischemic stroke reported in phase 2 trial with 11 mg dose 2

Contraindications and Cautions

Absolute contraindications:

• Severe hepatic impairment (Child-Pugh C) 5
• Active serious infections
• Known malignancy

Relative contraindications requiring careful risk-benefit assessment:

• Age >65 years with cardiovascular risk factors
• History of VTE or multiple VTE risk factors 4
• Severe renal impairment (requires dose adjustment to maximum 15 mg if eGFR <30) 5
• History of malignancy

Context Within Treatment Algorithm

The 2008 British guidelines recommend a stepwise approach for vitiligo 6:

1. First-line: Potent/very potent topical steroids (≤2 months) or topical calcineurin inhibitors
2. Second-line: NB-UVB phototherapy for widespread disease or significant QoL impact
3. Third-line: Surgical treatments for stable, localized disease (no new lesions for 12 months)

Upadacitinib fits as a third-line systemic option when:

• Topical therapies inadequate for extensive disease
• NB-UVB failed, contraindicated, or unavailable
• Patient has widespread disease with significant facial involvement
• Disease is active/progressive (not stable enough for surgery)

Key Clinical Pitfalls

Common mistakes to avoid:

• Using higher doses (>15 mg) expecting better results—this only increases adverse events 2
• Discontinuing too early—repigmentation is gradual and continues beyond 24 weeks 2
• Inadequate pre-treatment screening for TB and VTE risk factors
• Failing to counsel patients on realistic expectations (20-25% achieve ≥75% facial repigmentation)
• Not monitoring for herpes zoster reactivation

Practical Implementation

Patient counseling points:

• Repigmentation is gradual; expect months of treatment
• Face typically responds better than body
• Treatment must be continuous; stopping may lead to depigmentation
• Report signs of infection, chest pain, leg swelling immediately
• Use sun protection (vitiligo skin lacks melanin protection)

When to consider discontinuation:

• No response after 24-48 weeks
• Serious adverse events
• Development of contraindications
• Patient preference

The evidence strongly supports upadacitinib as an effective option for refractory vitiligo, particularly given the limited alternatives and significant QoL impact of this condition 1, 2, 3. The safety profile appears acceptable when patients are appropriately selected and monitored 1.